MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Patient Specific Compounding
20 questions · exam conditions
0:00
Patient Specific CompoundingQuestion 1 of 20

A compounding pharmacy prepares a customized cream for a named patient; which record is most necessary to demonstrate compliance with USP <795> documentation requirements for patient-specific dispensing?

Compounding record including ingredients, quantities, calculations, preparer/verifier, and beyond-use date
A generic formula card without dates, personnel, or lot numbers
A sales receipt only, with no linkage to the prescription
A prescriber directory listing clinic addresses
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Patient Specific Compounding

Practice Patient Specific Compounding in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Patient Specific Compounding, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A compounding pharmacy prepares a customized cream for a named patient; which record is most necessary to demonstrate compliance with USP <795> documentation requirements for patient-specific dispensing?

  1. Compounding record including ingredients, quantities, calculations, preparer/verifier, and beyond-use date (correct answer)
  2. A generic formula card without dates, personnel, or lot numbers
  3. A sales receipt only, with no linkage to the prescription
  4. A prescriber directory listing clinic addresses
Explanation: This question tests the ability to validate patient-specific prescription requirements for compounding workflows. Understanding the legal and regulatory framework for compounding is crucial, including USP standards and federal laws. In the context of the scenario, pharmacists must ensure compliance by verifying prescription details and maintaining accurate records. The correct answer reflects the necessary legal requirements, such as including patient information and prescriber approval, which are critical for compliance. A common misconception, as seen in incorrect choice B, is neglecting the need for specific documentation, leading to non-compliance issues. To support learning, encourage pharmacists to routinely review their state-specific regulations and participate in continuous education on federal compounding laws. Emphasize the importance of double-checking prescription details and maintaining thorough records for all compounded medications.

Question 2

A community pharmacist compounds for a pediatric patient; which regulatory body primarily enforces pharmacy practice and patient-specific compounding requirements at the state level?

  1. State Board of Pharmacy (correct answer)
  2. Internal Revenue Service
  3. Federal Trade Commission as the sole compounding regulator
  4. USP as an enforcement agency issuing pharmacy licenses
Explanation: This question tests the ability to validate patient-specific prescription requirements for compounding workflows. Understanding the legal and regulatory framework for compounding is crucial, including USP standards and federal laws. In the context of the scenario, pharmacists must ensure compliance by verifying prescription details and maintaining accurate records. The correct answer reflects the necessary legal requirements, such as including patient information and prescriber approval, which are critical for compliance. A common misconception, as seen in incorrect choice B, is neglecting the need for specific documentation, leading to non-compliance issues. To support learning, encourage pharmacists to routinely review their state-specific regulations and participate in continuous education on federal compounding laws. Emphasize the importance of double-checking prescription details and maintaining thorough records for all compounded medications.

Question 3

A compounding pharmacy prepares a dermatologic cream under USP <795>; which security and documentation control is most appropriate to protect patient-specific prescription records and controlled access?

  1. Role-based access to electronic records with audit trails and secure storage of hard copies (correct answer)
  2. Open-access shared login credentials to expedite workflow
  3. Discard compounding records after dispensing to reduce storage needs
  4. Store patient prescriptions in the public waiting area for easy retrieval
Explanation: This question tests the ability to validate patient-specific prescription requirements for compounding workflows. Understanding the legal and regulatory framework for compounding is crucial, including USP standards and federal laws. In the context of the scenario, pharmacists must ensure compliance by verifying prescription details and maintaining accurate records. The correct answer reflects the necessary legal requirements, such as including patient information and prescriber approval, which are critical for compliance. A common misconception, as seen in incorrect choice B, is neglecting the need for specific documentation, leading to non-compliance issues. To support learning, encourage pharmacists to routinely review their state-specific regulations and participate in continuous education on federal compounding laws. Emphasize the importance of double-checking prescription details and maintaining thorough records for all compounded medications.

Question 4

A veterinarian writes a prescription for a compounded transdermal methimazole gel for a feline patient. To be considered a valid patient-specific prescription, which of the following is required?

  1. A statement certifying that the animal is not a food-producing animal.
  2. The animal's specific breed and official registration number, if applicable.
  3. The veterinarian's state specialty license number in addition to their regular license.
  4. The name of the animal, the species of the animal, and the owner's name and address. (correct answer)
Explanation: A veterinary prescription has specific requirements to identify the patient. This includes the name or identification of the animal(s), the species, and the name and address of the owner or responsible party. This information is necessary to establish a valid patient-specific order for a compounded medication for an animal.

Question 5

A pharmacy that operates under Section 503A of the FD&C Act prepares a small batch of a popular compounded pain cream in anticipation of receiving prescriptions. To be compliant with federal law, the quantity prepared must be based on:

  1. a written request from a local physician's office for their anticipated needs over the next month.
  2. the pharmacy's purchasing history of the active ingredients over the previous quarter.
  3. a history of receiving valid prescriptions for that specific formulation within an established pharmacist-patient-prescriber relationship. (correct answer)
  4. a standing order from a local hospital that can be activated when a patient is identified.
Explanation: Section 503A allows for limited anticipatory compounding. The key requirement is that the amount compounded is based on a history of valid prescription orders for the compounded preparation. The pharmacy must be able to show a pattern of dispensing this specific formulation to individual patients based on prescriptions from their prescribers. Compounding for "office use" (A and D) is not permitted under 503A.

Question 6

A pharmacist receives a written prescription for a compounded pain cream containing ketamine (a Schedule III substance). To validate this patient-specific prescription, which of the following is federally required in addition to standard prescription elements?

  1. The patient's social security number for PDMP reporting purposes.
  2. A diagnosis code justifying the medical necessity for a C-III compound.
  3. The prescriber's valid DEA registration number and manual signature. (correct answer)
  4. The beyond-use date as determined and written by the prescriber.
Explanation: Prescriptions for controlled substances, including compounded ones, must adhere to DEA requirements. This includes the prescriber's full name, address, DEA registration number, and their manual signature (for written prescriptions). While a diagnosis code or social security number may be required by some state laws or insurance plans, they are not universal federal requirements for the validity of the prescription itself. The beyond-use date is determined by the pharmacist, not the prescriber.

Question 7

A prescriber writes an order for lisinopril 5 mg tablets to be compounded into a 1 mg/mL oral suspension for a geriatric patient with dysphagia. What is the most critical information the pharmacist must validate or document before compounding?

  1. The specific flavor requested by the patient or their caregiver to ensure adherence.
  2. The clinical need for a liquid formulation due to the patient's inability to swallow tablets. (correct answer)
  3. Confirmation that the patient's insurance will cover the compounded formulation over the tablet.
  4. The expiration date of the lisinopril stock bottle used for the compound.
Explanation: Compounding a drug from a solid dosage form into a liquid is permissible when there is a documented clinical need for the change. In this case, the patient's dysphagia (inability to swallow) provides the justification for not using the commercially available tablet. This justification is key to validating the prescription. The expiration date of the stock bottle is documented on the compounding record, not validated on the prescription itself.

Question 8

A physician prescribes a compounded version of a common blood pressure medication that is currently on the FDA drug shortage list. Under the FD&C Act, when may a pharmacist compound a drug that is a copy of a commercially available drug product?

  1. The pharmacist may compound the drug provided it is currently on the FDA's official drug shortage list. (correct answer)
  2. The pharmacist may never compound a copy of a commercially available product, even during a shortage.
  3. The pharmacist can only compound it if the patient has a documented allergy to an inactive ingredient.
  4. The pharmacist must first receive a special waiver from the state board of pharmacy before compounding.
Explanation: The FD&C Act generally prohibits compounding drugs that are essentially copies of commercially available products. However, an important exception is made for drugs that appear on the FDA's official drug shortage list. During a shortage, pharmacists are permitted to compound the drug to meet patient needs, provided they follow all other compounding laws and standards.

Question 9

A prescription reads: "Magic Mouthwash, QS to 240 mL. Swish and spit TID." It is written for a specific patient by a licensed oncologist. Before compounding this prescription, what is the pharmacist's primary legal responsibility?

  1. Use the pharmacy's standard magic mouthwash formula from the master formulation record.
  2. Inform the patient that the prescription is invalid and cannot be filled as written.
  3. Check the state's Prescription Drug Monitoring Program for other medications.
  4. Contact the prescriber to clarify the exact quantitative formula of active ingredients. (correct answer)
Explanation: A valid prescription for a compounded medication must specify the active ingredients and their quantities or strengths. "Magic Mouthwash" is a colloquial term for various formulations. The pharmacist cannot assume a standard formula and has a professional and legal duty to contact the prescriber to obtain a complete and unambiguous order before any compounding can occur.

Question 10

A physician writes a prescription for a compounded inhalation solution. The pharmacist, upon review, realizes the active ingredient is on the FDA's list of drug substances that are "demonstrably difficult to compound." What is the pharmacist's proper course of action?

  1. Compound the prescription but add an auxiliary label stating it is a high-risk preparation.
  2. Decline to fill the prescription and inform the prescriber that the drug is on the FDA's "difficult to compound" list. (correct answer)
  3. Request a signed waiver from the patient acknowledging the potential risks before compounding.
  4. Fill the prescription after documenting a special clinical need in the patient's profile.
Explanation: Under Section 503A of the FD&C Act, the FDA is authorized to create a list of drug products that present demonstrable difficulties for compounding that could adversely affect safety or effectiveness. Pharmacists are generally prohibited from compounding drugs that are on this list. The proper action is to refuse to fill the prescription and communicate the reason to the prescriber.

Question 11

A pharmacist has just prepared a patient-specific compounded topical solution. In addition to standard prescription label requirements (patient name, pharmacy info, etc.), which of the following is federally required by the FD&C Act to be on the label of the dispensed product?

  1. The internal lot number assigned by the pharmacy to the preparation.
  2. The full name of the compounding technician who prepared it.
  3. A statement indicating that the product is a compounded drug. (correct answer)
  4. The FDA MedWatch program telephone number for adverse event reporting.
Explanation: Section 503A of the Food, Drug, and Cosmetic Act explicitly requires that the label of a dispensed compounded drug include a statement that the drug is a compounded drug. Other items like the internal lot number and technician's name are good practice and often required by state law or pharmacy policy for inclusion on the compounding record, but the statement identifying it as a compound is a specific federal labeling requirement.

Question 12

A pharmacist in State A receives a valid patient-specific prescription for a non-controlled compounded medication for a patient residing in State B. The pharmacy holds licenses to practice in both states. Before compounding and shipping the prescription, the pharmacy must primarily ensure:

  1. the total quantity dispensed does not exceed a 30-day supply due to federal shipping laws.
  2. the patient has signed a waiver acknowledging the risks of receiving a compounded drug by mail.
  3. compliance with the pharmacy and compounding laws and regulations of both State A and State B. (correct answer)
  4. the US Postal Service is used as the courier, as private carriers have restrictions on medications.
Explanation: When dispensing prescriptions across state lines, a pharmacy is subject to the laws and regulations of both the state where the pharmacy is located (dispensing state) and the state where the patient resides (receiving state). The pharmacist must ensure all aspects of the prescription, compounding process, labeling, and shipping are compliant with the requirements of both states' boards of pharmacy.

Question 13

After preparing a patient-specific compounded suspension, the pharmacist must complete the compounding record for that prescription. The compounding record for this specific preparation MUST contain which of the following details?

  1. The marketing materials used to advertise the pharmacy's compounding services.
  2. A record of all other patients who have received this same formulation in the past.
  3. The lot numbers and expiration dates of the specific components used in the preparation. (correct answer)
  4. The wholesale acquisition cost of the bulk chemicals used in the preparation.
Explanation: The patient-specific compounding record (as distinct from the master formulation record) must document the details of a single compounding event. This includes traceability of all components. Therefore, it must list the specific ingredients, manufacturers, lot numbers, and expiration dates of the chemicals used to prepare that particular prescription for that patient. This ensures accountability and allows for investigation in case of a problem or recall.

Question 14

A hospital pharmacy needs a specific IV admixture for a patient. The pharmacy can either compound it in-house under 503A standards or purchase it from a 503B outsourcing facility. What is a key difference in the order requirements between these two options for a specific patient?

  1. A 503A preparation must be based on a valid patient-specific prescription, while a 503B product may be ordered as stock without a prescription. (correct answer)
  2. Prescriptions for 503A compounds can be verbal, but orders for 503B products must always be electronic.
  3. 503B products do not require a beyond-use date on the label, while 503A compounds do.
  4. All 503B products are considered controlled substances for ordering purposes, unlike 503A compounds.
Explanation: The fundamental difference between 503A and 503B facilities is the requirement for a patient-specific prescription. A 503A pharmacy (like a traditional pharmacy or hospital pharmacy compounding for a specific patient) MUST have a patient-specific prescription. A 503B outsourcing facility operates under Good Manufacturing Practices (GMP) and can produce batches of sterile drugs without prescriptions, which hospitals and clinics can then order as office stock.

Question 15

A nurse from a physician's office telephones the pharmacy with a new prescription for a patient-specific, non-controlled compounded gel. To validate this verbal order, the pharmacist must reduce it to writing and ensure it contains all necessary information, including:

  1. the nurse's professional license number and the specific reason for the telephone order.
  2. a statement from the nurse that a written prescription will be sent within 72 hours.
  3. the full name of the transmitting agent and a clear list of all active ingredients and their strengths. (correct answer)
  4. the diagnosis code to justify the combination of active ingredients prescribed by the physician.
Explanation: For a verbal prescription, including a compounded one, the pharmacist must transcribe it immediately. The transcribed order must contain all the elements of a valid prescription. This includes identifying the person transmitting the order (the agent of the prescriber, i.e., the nurse) and, critically for a compound, a complete and unambiguous list of all active ingredients and their intended strengths or concentrations.

Question 16

A pharmacist is validating a final compounded prescription for a patient in a state that requires a specific font size on the label of all compounded prescriptions. Federal law under Section 503A does not specify a font size. The pharmacist must:

  1. follow the federal law, as it preempts any conflicting state regulations on compounding.
  2. adhere to the stricter state law regarding the font size on the dispensed label. (correct answer)
  3. choose either standard to follow as long as the choice is documented in the pharmacy's policies.
  4. contact the FDA for clarification on which labeling standard to apply in this specific case.
Explanation: In pharmacy law, when federal and state laws both regulate an area, the pharmacist must follow the stricter of the two laws. Since federal law is silent on font size and the state law has a specific requirement, the state law is stricter and must be followed. Federal law does not preempt state law in this area; rather, it sets a minimum standard.

Question 17

A dermatologist's office sends a prescription via fax for "Compounded 5% Salicylic Acid Cream, 500 g, for office use." How must a pharmacist operating as a traditional 503A compounding pharmacy handle this request?

  1. Compound the preparation and label it "For Office Use Only by a Licensed Practitioner."
  2. Inform the prescriber that compounding must be done pursuant to a prescription for an individually identified patient. (correct answer)
  3. Fill the order as it is a valid request from a licensed prescriber for use in their practice.
  4. Contact a 503B outsourcing facility and have the product drop-shipped to the prescriber's office.
Explanation: Section 503A of the FD&C Act defines compounding as the preparation of a drug for an identified individual patient based on the receipt of a valid prescription order. Compounding medications for "office use" is considered manufacturing and is not permitted for a 503A pharmacy. The prescriber would need to obtain such products from a 503B outsourcing facility.

Question 18

A physician writes a prescription for a compounded version of a commercially available 20 mg tablet because the patient's insurance does not cover the manufactured product. The patient has no allergies or other clinical contraindications to the commercial product. How should the pharmacist validate this prescription?

  1. Fill the prescription as written, as cost is a valid reason for compounding for a specific patient.
  2. Decline to compound the medication, as it is considered a copy of a commercially available drug without a specific medical need. (correct answer)
  3. Compound a 10-day supply and inform the prescriber that a prior authorization for the commercial product is required for refills.
  4. Contact the insurance company on behalf of the patient to request an override for the commercially available product.
Explanation: Under the federal Food, Drug, and Cosmetic Act (FD&C Act), a pharmacy cannot compound a drug that is essentially a copy of a commercially available drug product. An exception exists if there is a patient-specific clinical need (e.g., allergy to an excipient) documented by the prescriber. Cost or insurance coverage issues are not considered valid clinical reasons to compound a copy.

Question 19

A pharmacist receives 50 prescriptions for the same compounded weight-loss cream from an out-of-state telemedicine physician for 50 different local patients. All prescriptions are to be shipped to a single address, which is a diet clinic. What is the pharmacist's primary legal concern when validating these prescriptions?

  1. Ensuring the shipping address is a valid residential or business location.
  2. Whether a legitimate patient-prescriber relationship exists for each individual prescription. (correct answer)
  3. Verifying that the physician holds a non-resident license in the pharmacy's state.
  4. Checking if the compounded ingredients are on the FDA's approved bulk substances list.
Explanation: The foundation of a valid prescription under Section 503A is the triad relationship: prescriber-patient-pharmacist. A large number of identical prescriptions from a remote prescriber for patients the prescriber may not have properly examined raises a significant red flag about the legitimacy of the patient-prescriber relationship. The pharmacist has a corresponding responsibility to ensure prescriptions are issued for a legitimate medical purpose.

Question 20

A pharmacist receives a new prescription for a patient-specific, non-controlled compounded topical cream. Which of the following components is required to be on the prescription order itself, rather than solely documented in the pharmacy's internal compounding record?

  1. The master formulation record reference for the preparation.
  2. The list of active ingredients and their respective strengths. (correct answer)
  3. The lot numbers and expiration dates of each ingredient used.
  4. The name of the technician who will prepare the compound.
Explanation: A valid patient-specific prescription for a compounded medication must contain the essential elements of a prescription, including the patient's name, prescriber's information, date, and the medication details. For a compound, this includes the name and strength of each active ingredient. The other items are part of the pharmacy's internal documentation (compounding record or master formulation record), not the prescription order itself.